Emerging drugs for the treatment of sarcopenia in cirrhosis of the liver

Simone Di Cola,Saniya Khan,Lucia Lapenna,Manuela Merli,Simone Di ColaSaniya KhanLucia LapennaManuela MerliDepartment of Translational and Precision Medicine,Sapienza University of Rome,Rome,Italy
DOI: https://doi.org/10.1080/14728214.2024.2332428
2024-03-30
Expert Opinion on Emerging Drugs
Abstract:KEYWORDS: Malnutrition is common in liver cirrhosis. Sarcopenia, defined as a generalized loss of skeletal muscle mass, significantly affects the progression of liver disease, increasing the risk of hospitalizations, liver decompensations, hepatic encephalopathy, bacterial infections, and mortality. A recent meta-analysis, including 22 studies and almost 7000 patients, reported that the presence of sarcopenia reduces 1, 3, and 5-year survival rates in patients with liver cirrhosis [ Citation 1 ], although the quality of the studies was not sufficient to provide robust evidence.
pharmacology & pharmacy
What problem does this paper attempt to address?